The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Advancing precision medicine: exploring ctDNA analysis beyond rectal cancer
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, discusses the use of circulating tumor DNA (ctDNA) in oncology. The use of ctDNA analysis has been extensively studied in rectal cancer and is now being explored in other cancer types, including biliary tract cancer. In this trial, precision medicine, utilizing ctDNA analysis, shows promise for improving clinical outcomes in the early stages of cancer. This represents a significant step forward in the field of precision medicine, aiming to achieve better outcomes for patients with early-stage cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
